Detalhe da pesquisa
1.
LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer.
Cell
; 172(4): 825-840.e18, 2018 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29336888
2.
Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors.
Invest New Drugs
; 41(2): 284-295, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36867316
3.
Nodal staging convergence for HPV- and HPV+ oropharyngeal carcinoma.
Cancer
; 127(10): 1590-1597, 2021 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33595897
4.
Stage I HPV-positive oropharyngeal cancer: Should all patients receive similar treatments?
Cancer
; 126(1): 58-66, 2020 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31536144
5.
Bromodomain inhibitors a decade later: a promise unfulfilled?
Br J Cancer
; 123(12): 1713-1714, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32989227
6.
Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer.
Breast Cancer Res Treat
; 184(1): 53-62, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-32803633
7.
Impact of insurance on survival in patients < 65 with head & neck cancer treated with radiotherapy.
Clin Otolaryngol
; 45(1): 63-72, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31661188
8.
Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules.
Invest New Drugs
; 37(1): 76-86, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29667134
9.
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors.
Oncology
; 97(2): 102-111, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31230047
10.
Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies.
Br J Clin Pharmacol
; 85(3): 530-539, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30428505
11.
Quantitative survival impact of composite treatment delays in head and neck cancer.
Cancer
; 124(15): 3154-3162, 2018 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29742280
12.
Perspectives in Head and Neck Medical Oncology.
Cancer Treat Res
; 174: 163-185, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29435842
13.
Treatment at high-volume facilities and academic centers is independently associated with improved survival in patients with locally advanced head and neck cancer.
Cancer
; 123(20): 3933-3942, 2017 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28640546
14.
Impact of concomitant chemoradiation on survival for patients with T1-2N1 head and neck cancer.
Cancer
; 123(9): 1555-1565, 2017 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28001302
15.
Combined high-intensity local treatment and systemic therapy in metastatic head and neck squamous cell carcinoma: An analysis of the National Cancer Data Base.
Cancer
; 123(23): 4583-4593, 2017 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28817183
16.
Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies.
Br J Cancer
; 117(9): 1258-1268, 2017 Oct 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-28859059
17.
Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.
Invest New Drugs
; 35(5): 616-626, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28194539
18.
Pharmacokinetic study of aldoxorubicin in patients with solid tumors.
Invest New Drugs
; 33(2): 341-8, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25388939
19.
Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors.
Int J Clin Pharmacol Ther
; 53(7): 563-72, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26073352
20.
Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy.
Cancer Immunol Immunother
; 63(8): 787-96, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24770667